Sepracor Says FDA Approves Sleep Drug  NEW YORK (Reuters) - Sepracor Inc., a specialty  pharmaceutical company, said on Wednesday it received a  long-awaited approval to market its Lunesta treatment for  insomnia, giving it a foothold in an estimated \$2 billion  market in the United States.